Kevin Harbour, MD
Pulmonary Disease · Tupelo, MSNPI 1508903626
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,244 of the $12,828 with a category attached, or 64.3%. 43 manufacturers reported payments, led by Intuitive Surgical at 36.7% of the total. Reporting peaked in 2023 at $5,967 and has fallen 70.0% since, to $1,788 in 2025.
Across 468 payments — averaging $27.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- GSK$1K
- AstraZeneca$1K
- Boehringer Ingelheim$958
- Actelion Pharmaceuticals US, Inc.$337
- Merck$321
- plus $4K from 37 others
What the payments were for
- Speaking & faculty fees$3002%
- Travel & lodging$1,0298%
- Food & beverage$8,24464%
- Education$3,25525%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,949
- DA VINCI SP$508
- Zemaira$149
- FASENRA$129
- BREZTRI$129
- TEZSPIRE$129
How this compares
$12,828 in reported general payments places this provider in the 75th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 340 | $252,235 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $191,509 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 86 | $41,575 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $16,410 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $12,094 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $7,522 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 177 | $5,704 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,461 |
| Ventolin HfaAlbuterol Sulfate | 45 | $2,362 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,409 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $739 |
| Montelukast Sodium | 59 | $292 |
| Azithromycin | 48 | $200 |
| Prednisone | 67 | $137 |
| Fluticasone Propionate | 16 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,494 | $305,905452 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $152 | $191,50913 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,148 | $19,87138 claims |
| Boehringer IngelheimStiolto Respimat | $958 | $7,52215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Tupelo
- Jaime UngoTupelo$29K
- William EdmonsonTupelo$15K
- Paul PerryTupelo$13K
- Robert StewartTupelo$10K
- David WittyTupelo$7K
- Ryan SessumsTupelo$4K
- Jose Henao CorreaTupelo$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.